| 抗丙型肝炎药物研究进展 |
| |
| 引用本文： | 郝兰虎,李艳萍,李卓荣. 抗丙型肝炎药物研究进展[J]. 中国抗生素杂志, 2011, 36(5) |
| |
| 作者姓名： | 郝兰虎 李艳萍 李卓荣 |
| |
| 作者单位： | 中国医学科学院,北京协和医学院医药生物技术研究所,北京,100050 |
| |
| 基金项目： | "重人新药创制"资助项目 |
| |
| 摘 要： | 近些年来,丙型肝炎病毒(HCV)生物学的快速进展使人们对HCV的感染和复制有了突破性认识,对抗HCV药物的研究与开发产生了重要影响.HCV NS3/4蛋白抑制剂telaprevir和boceprevir的开发进入临床Ⅲ期试验,一些NS5B抑制剂也进入临床研究,在很好降低感染病人病毒载量的同时显示出较好的耐受性.另外,通过干预与HCV复制有关的宿主细胞蛋白进行抗HCV的研究也受到普遍关注,并取得众多突破.本文将着重介绍一些近年来以病毒蛋白为靶点及以细胞因子为靶点的抗HCV约物的研究进展.
|
| 关 键 词： | 蛋白酶 聚合酶 宿主因子 抑制剂 |
The progress in anti-hepatitis C drugs |
| |
| Hao Lan-hu,Li Yan-ping,Li Zhuo-rong. The progress in anti-hepatitis C drugs[J]. Chinese Journal of Antibiotics, 2011, 36(5) |
| |
| Authors: | Hao Lan-hu Li Yan-ping Li Zhuo-rong |
| |
| Affiliation: | Hao Lan-hu,Li Yan-ping and Li Zhuo-rong(Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100050) |
| |
| Abstract: | In recent years,the development of the biology of HCV,has contributed breakthroughknowledge on the infection and replication of HCV,and makes an important impact on the development and reaearch of anti-hepatitis C viral drugs.Telaprevir and boceprevir,which belong to NS3/4 protease inhibitor,have reached Phase III.Several classes of small-molecule inhibitors of HCV NS5B have progressed into clinical development and demonstrated efficacy in reducing viral load in infected patients,and are well-tolerant.In ad... |
| |
| Keywords: | HCV |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
